Non-small cell lung cancer (NSCLC) patients with sensitizing mutations in the exons 18–21
of the epithelial growth factor receptor (EGFR) gene show increased kinase activity of EGFR …

Core–shell type lipid–polymer hybrid nanoparticles (CSLPHNPs) have emerged as a
multifunctional drug delivery platform. The delivery system combines mechanical …

Non-small cell lung cancer (NSCLC) is a global concern as one of the leading causes of
cancer deaths. The treatment options for NSCLC are limited to systemic chemotherapy …

Erlotinib (ELT) as a small molecule with poor solubility, poor bioavailability, and instability in
gastrointestinal environment, has been considered as a therapeutic agent for Non-Small …

Abstract Background and objectives Erlotinib HCl is approved for the treatment of metastatic
non-small cell lung cancer. Owing to its poor aqueous solubility and presystemic …

Erlotinib-based EGFR targeted therapy has proven significant clinical improvement against
non-small cell lung cancer (NSCLC). However, the anticancer activity of Erlotinib (Ertb) is …

This study was aimed at developing a nanoparticle strategy to overcome acquired
resistance against erlotinib in non-small cell lung cancer (NSCLC). To load erlotinib on …

In this study, epirubicin (EPI)-loaded solid lipid nanoparticles (EPI-SLNs) were successfully
prepared as an inhalable formulation for treatment of lung cancer. The physicochemical …

Combination therapy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
(EGFR TKIs) with other chemotherapeutic agents is a feasible strategy to overcome …

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in
China. This study aimed to develop a hyaluronic acid (HA) decorated, pH sensitive lipid …